Explore our premium grade lyophilized powders and peptide APIs manufactured under strict international quality guidelines.
An authoritative analysis of chemical manufacturing parameters, regulatory compliance, structural stability, and strategic procurement for biopharmaceutical buyers.
Eptifibatide (CAS: 148641-02-5) is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (*Sistrurus miliarius barbouri*). It belongs to the class of platelet aggregation inhibitors, functioning as a highly specific glycoprotein IIb/IIIa (integrin αIIbβ3) receptor antagonist. Chemically described as $N^6$-(aminoiminomethyl)-$N^2$-(1-oxo-3-mercatopropyl)-L-lysylglycyl-L-α-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1→6)-disulfide, its sequence incorporates a modified Lys-Gly-Asp motif that reversibly binds to human platelets to prevent fibrinogen binding and thrombus formation without eliciting strong immunogenic reactions.
The chemical synthesis of Eptifibatide present unique challenges, primarily regarding the formation of the intramolecular disulfide bridge between the mercaptopropionyl moiety and the C-terminal cysteinamide. High-yielding manufacturing routes employ a hybrid strategy combining Solid-Phase Peptide Synthesis (SPPS) using Fmoc/tBu chemistry on Rink Amide resin with controlled liquid-phase oxidation. Iodine-mediated oxidation or dimethyl sulfoxide (DMSO) oxidation under diluted basic conditions is precisely monitored via UHPLC to minimize parallel dimer formation and intermolecular aggregation, achieving native cyclization efficiency surpassing 92% yield prior to preparative purification.
China's top-tier peptide exporters adhere strictly to ICH Q3A/B guidelines. Final API validation demands high-performance liquid chromatography (HPLC) testing confirming structural identity via high-resolution Mass Spectrometry (HRMS) and 2D NMR spectroscopy. Critical quality attributes (CQAs) include overall purity ≥ 99.0%, maximum single unknown impurity ≤ 0.10%, residual trifluoroacetic acid (TFA) content ≤ 0.5% (or conversion to acetate salt), residual organic solvents (acetonitrile, DMF, DCM) below ICH limits, and bacterial endotoxin levels maintained under 0.05 EU/mg for parenteral drug preparation.
The global demand for antiplatelet therapeutics continues to grow steadily, propelled by the rising incidence of cardiovascular diseases (CVD), acute coronary syndromes (ACS), non-ST-segment elevation myocardial infarction (NSTEMI), and percutaneous coronary interventions (PCI). As original drug patents have expired worldwide, the market has transitioned toward high-quality generic peptide APIs. China has emerged as a powerhouse in commercial peptide API synthesis, commanding over 40% of the world's peptide crude and purified active substance supply chain.
Leading Chinese chemical manufacturers leverage fully automated multi-kilogram peptide synthesizers, continuous-flow oxidation reactors, and industrial-scale preparative HPLC systems (column diameters up to 600mm). This technical scalability dramatically lowers per-gram manufacturing overhead while maintaining regulatory compliance aligned with US FDA, EDQM, and WHO cGMP standards. Global pharmaceutical buyers—ranging from formulation developers in Latin America to drug exporters in EMEA—increasingly rely on China's integrated peptide supply ecosystems for consistent raw materials, custom peptide intermediates, and licensing assistance.
The peptide manufacturing landscape is undergoing a transformation toward greener chemical synthesis and digitalized process analytical technology (PAT). Future-proof exporters in China are actively implementing process improvements across three main technological frontiers:
Creating opportunities connecting the world with reliable services, standardized peptide manufacturing, and guaranteed quality.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Documents and Certificates are supported to customers worldwide.
Comprehensive technical support, product line architecture, analytical method validation, laboratory infrastructure consulting, and technology transfer solutions.
For those clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide extra customized procurement services with the most superior and comprehensive supply chain sources.
Stay informed with current scientific developments, peptide research updates, and API regulatory guides.
Introduction to Selank Acetate API Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient (API) composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Originally developed through neuropharmacological research, Selank is a derivative of the endogenous...
View Details
Trusted Thymosin Beta-4 API Manufacturer and Global Peptide Supplier As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Thymosin Beta-4 peptide API solutions for biotechnology companies, pharmaceutical research organizations, and li...
View Details
Introduction BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its potential biological activities related to tissue repair, gastrointestinal protection, angiogenesis, and inflammatory regulation. As a peptide ac...
View Details
With the continuous development of neuroscience, peptide technology, and life science research, neuroactive peptides have become an important area of scientific investigation. Semax, a synthetic peptide derived from an ACTH fragment, has attracted attention among researchers due to its unique mol...
View Details
SS-31 API, also known as Elamipretide, MTP-131, Bendavia, and SS31, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane. By stabilizing mitochondrial structure and supporting cellular bioenergetics, SS-31 ha...
View DetailsEngineered for global reliability with compliant logistical channels servicing North America, Europe, Mexico, South Africa, and Asia-Pacific.
Detailed technical, regulatory, and commercial responses tailored for pharmaceutical buyers and peptide scientists.
Every commercial batch of bulk Eptifibatide API exported from China is delivered with a complete Certificate of Analysis (CoA) containing validated analytical data: RP-HPLC chromatograms (purity ≥ 99.0%), Mass Spectrometry (MS) structural verification, Amino Acid Analysis (AAA), Karl Fischer water content (≤ 5.0%), residual solvents (ICH Q3C), heavy metal limits, and bacterial endotoxin testing via LAL assay.
In high-scale Eptifibatide peptide synthesis, unwanted intermolecular dimer formation is suppressed by operating intramolecular oxidative cyclization at high dilution (≤ 1 mM substrate concentration) using air or controlled DMSO oxidation at pH 7.5–8.2. Additionally, temperature-controlled continuous flow reactors ensure uniform mixing, keeping total dimer/multimer impurities under 0.20%.
Lyophilized Eptifibatide API remains stable for up to 36 months when stored in sealed, light-resistant glass vials or aluminum foil laminate bags under cold conditions (-20°C ± 5°C) under inert argon gas. For short-term transit, ambient temperature stability is verified for up to 14 days without measurable degradation.
Yes. While initial trifluoroacetic acid (TFA) cleavage leaves TFA counter-ions bound to basic lysine and amine residues, our ion-exchange prep-HPLC systems allow full conversion to Acetate ($CH_3COO^-$) or Hydrochloride ($Cl^-$) salt forms. Final TFA content is guaranteed to be under 0.1% or non-detectable depending on clinical formulation requirements.
Gentolex provides comprehensive regulatory support packages, including Type II Drug Master Files (DMF) for the US FDA, CEP applications for EDQM, and local drug registration dossiers across Latin America (e.g., Mexico COFEPRIS) and Africa (South Africa SAHPRA). Our regulatory experts assist with deficiency letters and post-approval variations.
High-grade active ingredients designed for parenteral formulations, research institutions, and global export.
